The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
“On face value the data look very good,” said Buzdar, who voted with the slim (5-4) majority against the drug. In the study that was the basis of Genentech’s application, Avastin appeared to slow the progress of the disease. advanced breast cancer who had already tried other drugs. He said he’s never...
The HeptoVax trial is Phase II study in which GV1001 (a telomerase peptide vaccine administered with GM-CSF) was given to patients suffering from advanced hepatocellular carcinoma (HCC or liver cancer). The trial update indicates safety of the vaccine but no efficacy data are available. Such...
The current report in NEJM demonstrates that Erbitux + best supportive care improves survival (6.1 months) for patients with previously treated metastatic colorectal carcinoma as compared with BSC alone (4.6 months). These data represent the first report of a survival advantage in a solid tumor...
Uveal melanoma is an uncommon disease but is devastating when it metastasizes. The most common site of metastases is the liver and response rates to conventional chemotherapy agents are poor. This trial is designed specifically to assess the activity of Marqibo in patients with metastatic...
Avastin now has been approved in Europe for the treatment of metastatic renal cell carcinoma. Avastin + Interferon nearly doubles the PFS vs Interferon alone. Approval in Europe (and similar FDA approval) will be critical to the marketing of this expensive agent. However, these data...
I think this a very important advance in a tumor where there is no adequate treatment. however, we have to realize that the studies were done in japan, and the natural history of gastri cancer in japan is quite different that gastic cancer in USA
Trials of Telik were halted by the FDA in June 2007 after patients receiving the agent in an ovarian cancer trial were found to have ahigher death rate than those that did not receive Telik. The current decision allows Telik trials to resume, but efficacy is still in question.
New therapies are needed for the treatment of glioblastoma multiforme. Surgery, radiation and temozolamide remain the mainstay of treatment. Results from the current pilot study suggest that Avastin may have efficacy in GBM.
MT-103 is an anti-CD19 monoclonal antibody that has demonstrated clinical activity in phase I trials in patients with NHL. The proposed phase II trial in ALL will assess whether MT103 can remove residual tumor cells and thereby convert patients from a MRD (minimal residual disease)- positive to...